[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05937945":3,"trial-entities:NCT05937945":85,"trial-summary:NCT05937945":88},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":21,"primary_purpose":15,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":27,"secondary_outcomes":34,"sex":35,"minimum_age":36,"maximum_age":15,"healthy_volunteers":15,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":66,"overall_officials":70,"references":73,"see_also_links":84},"NCT05937945","83312301","Studying Patient Experiences in Osteoporosis Clinical Trials","Uncovering Osteoporosis Clinical Trials: Firsthand Patient Insights Into Clinical Trial Experiences","UNKNOWN","2026-07","2023-06","2023-07-10","2024-07","Power Life Sciences Inc.","INDUSTRY",null,"Clinical trials for osteoporosis are designed to assess the safety and effectiveness of novel osteoporosis treatments. These trials play a crucial role in establishing whether these new treatments outperform existing options and provide substantial evidence to support their adoption within the wider population.\n\nThe primary aim of this particular study is to investigate the experiences of individuals diagnosed with osteoporosis who participate in a distinct clinical trial involving a medical intervention. The focus will be on closely monitoring the rates of trial completion and withdrawal among these participants.",[18],"Osteoporosis",[20],"osteoporosis","OBSERVATIONAL",[],{"count":24,"type":25},500,"ESTIMATED",[],[28,31],{"measure":29,"timeFrame":30},"Number of patients who decide to join in an osteoporosis clinical trial","3 months",{"measure":32,"timeFrame":33},"Rate of patients who remain in osteoporosis clinical trial to trial completion","12 months",[],"ALL","18 Years",{"inclusion":38,"exclusion":42,"raw_text":46},[39,40,41],"Patient has been diagnosed with osteoporosis","Patient has self-identified as planning to enroll in an observational clinical trial","Patient is a minimum of 18 years or older",[43,44,45],"Pregnant or nursing patients","Inability to perform regular electronic reporting","Patient does not understand, sign, and return consent form","Inclusion Criteria:\n\n* Patient has been diagnosed with osteoporosis\n* Patient has self-identified as planning to enroll in an observational clinical trial\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":63},"Power Life Sciences","San Francisco","California","94107","United States",[58],{"name":59,"role":60,"phone":61,"email":62},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":64,"lon":65},37.77493,-122.41942,[67],{"name":59,"role":60,"phone":68,"email":69},"4159004227","bask@withpower.com",[71],{"name":59,"affiliation":13,"role":72},"STUDY_DIRECTOR",[74,78,81],{"pmid":75,"type":76,"citation":77},"36187130","BACKGROUND","Liu C, Liu N, Xia Y, Zhao Z, Xiao T, Li H. Osteoporosis and sarcopenia-related traits: A bi-directional Mendelian randomization study. Front Endocrinol (Lausanne). 2022 Sep 14;13:975647. doi: 10.3389\u002Ffendo.2022.975647. eCollection 2022.",{"pmid":79,"type":76,"citation":80},"35513573","Bell A, Kendler DL, Khan AA, Shapiro C M M, Morisset A, Leung JP, Reiner M, Colgan SM, Slatkovska L, Packalen M. A retrospective observational study of osteoporosis management after a fragility fracture in primary care. Arch Osteoporos. 2022 May 6;17(1):75. doi: 10.1007\u002Fs11657-022-01110-z.",{"pmid":82,"type":76,"citation":83},"32663187","Amer M, Noor S, Kashif SM, Nazir SUR, Ghazanfar T, Yousaf S. Evaluation of Disease Related Knowledge in Patients of Osteoporosis: An Observational Study. Altern Ther Health Med. 2021 Jun;27(S1):97-103.",[],{"nct_id":4,"conditions":86,"biomarkers":87},[18],[],{"nct_id":4,"found":89,"summary":90,"prompt_version":99},true,{"design":91,"status":92,"heading":6,"summary":93,"follow_up":94,"word_count":95,"commitments":96,"compensation":97,"drugs_mentioned":98},"This is an observational study, meaning we will be watching and collecting information about participants' experiences in other clinical trials. We plan to include 500 participants.","completed","This study is looking at the experiences of people with osteoporosis who decide to join other clinical trials that test new medical treatments. We want to understand how many people choose to join these trials and how many stay in them until the end. This helps us learn more about what it's like for patients participating in research. You can join if you are at least 18 years old, have osteoporosis, and are planning to enroll in an observational clinical trial. We are not testing a new drug in this study, but rather observing participants' experiences in other trials. We aim to include 500 participants.","We will measure how many patients join a trial at 3 months and how many remain in a trial until completion at 12 months.",105,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]